ASH 2018 | Anas Younes: two practice-changing abstracts at ASH 2018
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
In this interview, Anas Younes, MD, of the Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the two abstracts that in his opinion are practice-changing in the areas of T-cell lymphoma and chronic lymphocytic leukemia (CLL), presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. These are the ECHELON-2 (NCT01777152) clinical trial results, focusing on the use of brentuximab vedotin and CHP in peripheral T-cell lymphomas, and the data on the use of ibrutinib and rituximab for the frontline treatment of CLL.
Get great new content delivered to your inboxSign up